Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses

There is increasing evidence that the risk of SARS-CoV-2 infection among vaccinated individuals is variant-specific, suggesting that protective immunity against SARS-CoV-2 may differ by variant. We enrolled vaccinated (n = 39) and unvaccinated (n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. For individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all circulating variants, including BA.2.

[1]  B. Walker,et al.  T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals , 2022, Cell.

[2]  J. Zahradník,et al.  Virological characteristics of SARS-CoV-2 BA.2 variant , 2022, bioRxiv.

[3]  M. Diamond,et al.  Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice , 2022, bioRxiv.

[4]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[5]  D. Barouch,et al.  Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, medRxiv.

[6]  S. Madhi,et al.  SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers , 2022, medRxiv.

[7]  J. Mascola,et al.  mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron , 2022, bioRxiv.

[8]  B. Walker,et al.  T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals , 2022, Cell.

[9]  A. Sette,et al.  T cell responses to SARS-CoV-2 spike cross-recognize Omicron , 2022, Nature.

[10]  C. Riou,et al.  Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose , 2022, The Lancet.

[11]  S. Madhi,et al.  SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.

[12]  Katherine C DeRuff,et al.  Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak , 2021, Cell.

[13]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[14]  M. Kraemer,et al.  Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.

[15]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[16]  S. Haneuse,et al.  Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections , 2021, JCI insight.

[17]  Pardis C Sabeti,et al.  Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness , 2021, medRxiv.

[18]  P. Shah,et al.  Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients , 2021, Transplantation.

[19]  M. Hoelscher,et al.  Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  C. Broder,et al.  The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Segev,et al.  Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. , 2021, JAMA.

[22]  R. Darnell,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[23]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[24]  Liyan Wen,et al.  Kinetics of viral load and antibody response in relation to COVID-19 severity. , 2020, The Journal of clinical investigation.

[25]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[26]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .